InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | van Houte Hans | Chief Financial Officer | Sale | 2,388 | $16.65 | $40K | 51.6K | View ↗ | |
| 2026-04-30 | Ring Christine | Chief Legal Officer | Sale | 3,214 | $16.65 | $53K | 31.8K | View ↗ | |
| 2026-01-30 | Hansen Gwenn | Chief Scientific Officer | Sale | 4,895 | $16.60 | $81K | 83.7K | View ↗ | |
| 2025-10-30 | Hansen Gwenn | Chief Scientific Officer | Sale | 4,087 | $12.80 | $52K | 76.8K | View ↗ | |
| 2025-07-30 | Hansen Gwenn | Chief Scientific Officer | Sale | 4,308 | $12.01 | $52K | 69.0K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total revenue | $30.0M | $0-100.0% | $20.0M | $0 |
| Research and development | $316.9M+43.0% | $221.6M+17.2% | $189.1M+2.5% | $184.5M |
| General and administrative | $52.7M+14.8% | $45.9M+7.1% | $42.9M+12.9% | $38.0M |
| Total operating expenses | $369.6M+38.1% | $267.6M+15.3% | $232.1M+4.3% | $222.5M |
| Loss from operations | -$285.7M-34.1% | -$213.0M-37.4% | -$155.1M+15.7% | -$183.9M |
| Interest and other income, net | $22.0M+11.4% | $19.7M+77.5% | $11.1M+216.9% | $3.5M |
| Loss before income taxes | -$263.7M-36.4% | -$193.3M-34.3% | -$143.9M | — |
| Provision for income taxes | $760K+181.5% | $270K | $0 | $0 |
| Net loss | -$264.5M-36.6% | -$193.6M-34.5% | -$143.9M+20.2% | -$180.4M |
| Net loss per share, basic (in USD per share) | -$3K-5.9% | -$3K-8.7% | -$3K-71328.6% | -$3.71 |
| Net loss per share, diluted (in USD per share) | -$3K-5.9% | -$3K-8.7% | -$3K-71328.6% | -$3.71 |
| Weighted-average number of shares outstanding, basic (in shares) | $86.67B+29.1% | $67.12B+23.5% | $54.34B+111688.0% | $48.6M |
| Weighted-average number of shares outstanding, diluted (in shares) | $86.67B+29.1% | $67.12B+23.5% | $54.34B+111688.0% | $48.6M |
| Collaboration revenue | ||||
| Total revenue | $30.0M | $0-100.0% | $20.0M | $0 |
| License revenue | ||||
| Total revenue | $30.0M | $0-100.0% | $20.0M | $0 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Nurix Therapeutics Inc. (NRIX): Leadership in Targeted Protein Degradation Attracts Smart Money
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript